The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.

Caroline S BennetteCarlos J GallegoWylie BurkeGail P JarvikDavid L Veenstra

Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2014)

Returning incidental findings is likely cost-effective for certain patient populations. Screening of generally healthy individuals is likely not cost-effective based on current data, unless next-generation sequencing costs less than $500.

Keyphrases

copy number
case report
electronic health record
single cell
big data
circulating tumor
dna methylation
genome wide
gene expression
machine learning